Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Department of Medicine, University College Hospital, Ibadan, Nigeria.
Afr Health Sci. 2023 Mar;23(1):72-82. doi: 10.4314/ahs.v23i1.9.
Data regarding the features and outcomes of hospitalized COVID-19 patients in Africa are increasingly available.
To describe socio-demographic, clinical and laboratory characteristics and outcomes of COVID-19 patients.
A cross-sectional study of 86 adult patients hospitalized with COVID-19 between March and November 2020. Characteristics were described in survivors and non-survivors.
Mean age was 60.9±16.1 years, 53(61.6%) were male. Co-morbidities were found in 77(89.5%) patients. On severity, 6(7%) were mild, 23(26.7%) moderate, 51(59.3%) severe and 6(7%) critical. Oxygen saturation and respiratory rate were 71±22% and 38±11/minute in non-survivors and 90±7% and 31±7/minute in survivors respectively (p<0.001, p<0.001)). Overall mortality was 47.7% with no death among patients with mild disease and deaths in all patients with critical disease. Duration of hospitalization was 2.0(1.0-4.5) days in those who died and 12(7.0-15.0) days in those who survived (p<0.001). Of the 42 patients that received dexamethasone, 11(26.2%) died, while 31(73.8%) survived (p=<0.001).
Most of the patients had co-morbidities and there was high mortality in patients with severe and critical COVID-19. Mean oxygen saturation was low and respiratory rate high overall. Factors associated with mortality included: Significantly greater hypoxia and tachypnea, less dexamethasone use and shorter hospitalization.
关于非洲住院 COVID-19 患者的特征和结局的数据越来越多。
描述 COVID-19 患者的社会人口学、临床和实验室特征及结局。
对 2020 年 3 月至 11 月期间因 COVID-19 住院的 86 例成年患者进行横断面研究。描述幸存者和非幸存者的特征。
平均年龄为 60.9±16.1 岁，53 例（61.6%）为男性。77 例（89.5%）患者存在合并症。严重程度方面，6 例（7%）为轻症，23 例（26.7%）为中度，51 例（59.3%）为重症，6 例（7%）为危重症。非幸存者的血氧饱和度和呼吸频率分别为 71±22%和 38±11/min，幸存者分别为 90±7%和 31±7/min（p<0.001，p<0.001）。总死亡率为 47.7%，轻症患者无一例死亡，危重症患者全部死亡。死亡患者的住院时间为 2.0（1.0-4.5）天，存活患者为 12（7.0-15.0）天（p<0.001）。接受地塞米松治疗的 42 例患者中，11 例（26.2%）死亡，31 例（73.8%）存活（p<0.001）。
大多数患者存在合并症，重症和危重症 COVID-19 患者死亡率较高。总体而言，血氧饱和度较低，呼吸频率较高。与死亡率相关的因素包括：明显的缺氧和呼吸急促、较少使用地塞米松和较短的住院时间。
